UNSPSC 51152042: Oxydipentonium

This classification denotes a muscle relaxant with the molecular formula C16H38N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 52J3C7381O, chemically known as trimethyl-[5-[5-(trimethylazaniumyl)pentoxy]pentyl]azanium but generally known as oxydipentonium, which bears US NIH Compound Identifier 23560. European Medicines Agency schedules Oxydipentonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09563MIG. The term OXYDIPENTONIUM is an International Non-Proprietary Name.

As of Q4 2014, OXYDIPENTONIUM remains the US FDA Preferred Term for this commodity. Oxydipentonium bears US NLM identifiers UMLS ID C2828260 and NCI Concept Code C87313. SMILES: C[N+](C)(C)CCCCCOCCCCC[N+](C)(C)C.[Cl-].

UNSPSC 51152042 Oxydipentonium, a Commodity code, shows recent state and local procurement focused on naloxone and drug deactivation systems for community health and pharmaceutical benefit programs, though the code name and actual solicitation scope diverge significantly. State and local governments under this code are buying pharmaceutical products and related delivery systems to support opioid response initiatives and prescription management programs. Issuing bodies include county health departments and state health and human services agencies. Seminole County, Florida and the Texas Health and Human Services Commission have posted recent opportunities under this code, indicating activity from both local and state-level public health and benefits administration functions.

Procurement activity appears concentrated in Florida and Texas. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023, and a two-year initial contract term with one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program involving direct contracting between state pharmacy benefit programs and manufacturers, though this RFI is exploratory and does not establish formal evaluation criteria or funding levels. The Seminole County procurement includes standard compliance requirements (E-Verify, drug-free workplace certification, workers' compensation and general liability insurance) and a three-month probationary period; potential FEMA funding introduces federal environmental compliance obligations. Recent opportunities show limited geographic spread and suggest the code captures both operational pharmaceutical procurement and preliminary market research for larger state-level prescription management initiatives.